公开(公告)号：US20150368323A1

公开(公告)日：2015-12-24

申请号：US14647459

申请日：2013-12-20

Applicant: MORPHOSYS AG

Inventor： Christoph Michael ERNST ,  Andreas Paul PESCHEL ,  Alexandra KRAUS ,  Michael TESAR

IPC: C07K16/12 ,  A61K38/12 ,  A61K39/40

CPC classification number: C07K16/1271 ,  A61K38/12 ,  A61K39/40 ,  A61K2039/505 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76

Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.

Abstract translation: 本公开内容通常涉及与细菌蛋白MprF相互作用的抗体或其片段。 本公开进一步公开了结合MprF的特异性细胞外基序的抗体。 本公开还涉及包含MprF特异性抗体的治疗剂和使用MprF特异性抗体或其片段的治疗方法。

公开(公告)号：US20150238603A1

公开(公告)日：2015-08-27

申请号：US14430801

申请日：2013-09-24

Applicant: MORPHOSYS AG

Inventor： Jan Endell ,  Lisa Rojkjaer

IPC: A61K39/395 ,  A61K31/198

CPC classification number: A61K39/39558 ,  A61K31/198 ,  A61K39/3955 ,  A61K2039/545 ,  C07K16/2896 ,  A61K2300/00

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and melphalan.

Abstract translation: 本公开描述了抗CD38抗体和美法仑的药物组合。

公开(公告)号：US20150197579A1

公开(公告)日：2015-07-16

申请号：US14418089

申请日：2013-08-08

Applicant: MorphoSys AG

Inventor： Haertle Stefan ,  Christian Frisch ,  Achim Knappik

IPC: C07K16/42 ,  G01N33/68 ,  C07K16/24

CPC classification number: C07K16/4241 ,  C07K16/241 ,  C07K16/243 ,  C07K16/42 ,  C07K2317/30 ,  C07K2317/32 ,  C07K2317/55 ,  G01N33/686

Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and thus can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for use of said antibodies and antibody fragments.

Abstract translation: 本发明提供了特异性检测特异性同源抗原结合部分，特别是抗体及其抗原的复合物的抗体及其片段。 本公开的抗体不单独与所述同源抗原结合部分或所述抗原结合，因此可以例如使用。 以直接检测抗原结合的抗原结合部分。 进一步披露的是使用所述抗体和抗体片段的方法。

公开(公告)号：US20150017160A1

公开(公告)日：2015-01-15

申请号：US14500366

申请日：2014-09-29

Applicant: MORPHOSYS AG

Inventor： Lisa Rojkjaer ,  Rainer Boxhammer ,  Jan Endell ,  Mark Winderlich ,  Christofer Samuelsson

IPC: A61K39/395 ,  A61K31/454

CPC classification number: C07K16/40 ,  A61K31/454 ,  A61K31/69 ,  A61K38/05 ,  A61K38/07 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2896 ,  C07K16/3061 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  A61K2300/00

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.

Abstract translation: 本公开描述了抗CD38抗体和来那度胺的药物组合以及抗CD38抗体和硼替佐米的药物组合。

公开(公告)号：US20140206575A1

公开(公告)日：2014-07-24

申请号：US14242906

申请日：2014-04-02

Applicant: MorphoSys AG

Inventor： Stefanie Urlinger ,  Thomas Tiller ,  Ingrid Schuster ,  Yvonne Stark

IPC: C07K16/00 ,  C12N15/10

CPC classification number: G01N33/6854 ,  C07K16/005 ,  C07K2317/55 ,  C07K2317/567 ,  C12N15/1037 ,  C40B40/08

Abstract: The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.

Abstract translation: 本公开使得可变重链和可变轻链对的收集部分包含预先选择用于与显影性相关的功能性质的种系蛋白序列，其中所述集合可以用于使用例如， 噬菌体展示。

公开(公告)号：US11939395B2

公开(公告)日：2024-03-26

申请号：US17343163

申请日：2021-06-09

Applicant: MORPHOSYS AG

Inventor： Michael Tesar ,  Ute Jäger

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/3061 ,  C07K16/2896 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732

Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

公开(公告)号：US20230357392A1

公开(公告)日：2023-11-09

申请号：US18087068

申请日：2022-12-22

Applicant: MORPHOSYS AG

Inventor： Stefan HÄRTLE ,  Frank STRIEBEL

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/454

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61K31/454 ,  A61K2039/545

Abstract: The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.

公开(公告)号：US20230203149A1

公开(公告)日：2023-06-29

申请号：US16647775

申请日：2018-09-25

Applicant: MORPHOSYS AG ,  GALAPAGOS NV

Inventor： Stefan Haertle ,  Tim Van Kaem ,  Frederic Paul Vanhoutte

IPC: C07K16/24 ,  A61P17/06 ,  A61K9/00

CPC classification number: C07K16/244 ,  A61P17/06 ,  A61K9/0019 ,  A61K2039/545

Abstract: The present invention provides a pharmaceutical composition comprising an antibody for antibody fragment specific for IL-17C, in particular MOR106 for use in the treatment of atopic dermatitis and related conditions wherein the antibody is administered to patients at dosages that are beneficial in a clinical setting.

公开(公告)号：US20220283166A1

公开(公告)日：2022-09-08

申请号：US17824266

申请日：2022-05-25

Applicant: MORPHOSYS AG

Inventor： Jan ENDELL ,  Mark WINDERLICH ,  Rainer BOXHAMMER

IPC: G01N33/574 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28

Abstract: The present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with an anti-CD19 antibody.

公开(公告)号：US20220213190A1

公开(公告)日：2022-07-07

申请号：US17700809

申请日：2022-03-22

Applicant: MorphoSys AG

Inventor： Patrick GARIDEL ,  Andreas LANGER ,  Martin HESSLING ,  Daniel WEINFURTNER ,  Bodo BROCKS

IPC: C07K16/28 ,  A61K47/54 ,  A61K9/19 ,  A61K31/715 ,  A61K47/36

Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.